U.S. v. Dentsply: False Tooth Distribution Practices Violate Antitrust Laws
This article was originally published in The Gray Sheet
Executive Summary
A federal appeals court ruling that artificial tooth maker Dentsply must end its exclusivity provisions for dealers could impact similar arrangements by other device firms, some industry attorneys say
You may also be interested in...
Dentsply Distribution Practices Violate Antitrust Laws, Justice Says
Dentsply's distribution policies for its Trubyte line of artifical teeth violate U.S. antitrust laws, the Justice Department maintains in a complaint filed Jan. 5 in Delaware federal court.
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.